SIETES :: 92954 citas

Resultados de la búsqueda por ETIOPATOGENIA NEUROLÓGICAS REFINAR BÚSQUEDA

1.

Garcez H, Fernandes C, Barbosa F, Pereira MR, Silveira C, Marques-Texeira J. Effects of benzodiazepines administration on identification of facial expressions of emotion: a meta-analysis. Psychopharmacology (Berl) 2019:noviermbre. [Ref.ID 103227]

2.

Ji Y, Azuine RE, Zhang Y, Hou W, Hong X, Wang G, Riley A, Pearson C, Zuckerman B, Wang X. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2019:30 de octubre. [Ref.ID 103208]

3.

Rubin R. Uncovering a link between the appendix and Parkinson disease risk. JAMA 2019:3 de julio. [Ref.ID 103151]

4.

Tetz G, Brown SM, Hao Y, Tetz V. Parkinson’s disease and bacteriophages as its overlooked contributors. Nature Scientific Reports 2018;8:17 de julio. [Ref.ID 102812]

5.

Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. Anti–tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurology 2018;75:939-46. [Ref.ID 102569]

6.

Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]

7.

Wilke RA, Freeman JW. Potential health implications related to fracking. JAMA 2017;318:1645-6. [Ref.ID 102135]

8.

Park H-Y, Park J-W, Sohn HS, Kwon JW. Association of parkinsonism or Parkinson disease with polypharmacy in the year preceding diagnosis: a nested case–control study in South Korea . Drug Saf 2017;40:1109-18. [Ref.ID 102104]

9.

Jhang KM, Huang J-Y, Nfor ON, Tung Y-C, Ku W-Y, Lee C-T, Liaw Y-P. Extrapyramidal symptoms after exposure to calcium channel blocker-flunarizine or cinnarizine. Eur J Clin Pharmacol 2017;73:911-6. [Ref.ID 101996]

10.

Lin H-L, Lin H-C, Tseng Y-F, Chen SC, Hsu C-Y. Risk of parkinsonism induced by flunarizine or cinnarizine: a population-based study. Eur J Clin Pharmacol 2017;73:365-71. [Ref.ID 101941]

11.

Chen HK, Kwong JC, Copes R, Tu K, Villeneuve PJ, van Donkelaar A, Hystad P, Martin RV, Murray BJ, Jessiman B, Wilton AS, Kopp A, Burnett RT. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Lancet 2017;389:718-26. [Ref.ID 101409]

12.

Huybrechts KF, Hernández-Díaz S, Patorno E, Desai RJ, Mogun H, Dejene SZ, Cohen JM, Panchaud A, Cohen L, Bateman BT. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 2016:17 de agosto. [Ref.ID 100582]

13.

de Maleissye M-F, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med 2016;375:296-7. [Ref.ID 100503]

14.

Andersen NN, Pasternak B, Andersson M, Nielsen NM, Jess T. Risk of demyelinating diseases in the central nervous system in patients with inflammatory bowel disease treated with tumor necrosis factor inhibitors. JAMA Intern Med 2015;175:1990-2. [Ref.ID 99751]

15.

Lee YC, Lin CH, Wu RM, Lin MS, Lin JW, Chang CH, Lai MS. Discontinuation of statin therapy associates with Parkinson disease: a population-based study. Neurology 2013;81:410-6. [Ref.ID 95841]

16.

Anónimo. Pour mieux soigner: des médicaments à écarter. Prescrire 2013;33:138-42. [Ref.ID 94882]

17.

Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012;157:498-511. [Ref.ID 93827]

18.

Pérez-Lloret S, Rey MV, Montastruc J-L. Syndrome des jambes sans repos: Les médicaments aussi !. BIP31.fr 2012;19:48. [Ref.ID 93270]

19.

Yuki N, Hartung H-P. Medical progress: Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304. [Ref.ID 93212]

20.

Anónimo. Metoclopramida: restricciones de uso en niños y adolescentes. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2011:27 de octubre. [Ref.ID 91575]